- Home
- ARCT vs NYXH Comparison
ARCT vs NYXH Comparison
Compare ARCT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARCT | NYXH |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 161.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARCT | NYXH |
|---|---|---|
| Price | $15.81 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $24.11 | $9.33 |
| AVG Volume (30 Days) | ★ 1.4M | 185.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | $12.77 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $1.26 |
| 52 Week High | $24.14 | $6.87 |
Technical Indicators
Market Signals| Indicator | ARCT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 70.15 | 58.75 |
| Support Level | $6.47 | $1.28 |
| Resistance Level | N/A | $1.70 |
| Average True Range (ATR) | 1.60 | 0.07 |
| MACD | 0.35 | 0.00 |
| Stochastic Oscillator | 76.36 | 59.12 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.